lupin

Lupin launches asthma treatment drug in US

The company has launched its generic product after receiving the approval from the USFDA.

Chart Check: Here's what you should do with Tata Chemicals and Tata Global

On May 16, S&P BSE Oil & Gas rose 1.5 percent, followed by the S&P BSE realty that gained 1.3 percent, and the S&P BSE Power that was up 1.3 percent

Lupin shares tank 6% after observations from USFDA for Aurangabad plant

On the NSE, shares tanked 5.84 percent to Rs 736.40.

Lupin falls after Q4 results, USFDA observations; CLSA maintains sell call

CLSA maintained its sell rating on Lupin post March quarter results but slashed its target price to Rs 700 from Rs 730 earlier.

Lupin denies price manipulation allegations, says will defend antitrust lawsuit in US

Lupin was named as a defendant with respect to 11 generic drugs for alleged price manipulation.

Lupin gets 3 observations from USFDA for Aurangabad plant

The USFDA carried out the inspection at the plant from May 6 to May 15.

Reviewing details of lawsuit filed in the US: Lupin

The company has been a key pharmaceutical player in the US and has demonstrated full commitment to compliance with all laws and ethical business practices, it added.

Lupin Consolidated March 2019 Net Sales at Rs 4,406.32 crore, up 9.23% Y-o-Y

Lupin Standalone March 2019 Net Sales at Rs 2,971.86 crore, up 19.95% Y-o-Y

Lupin Q4 preview: Net profit likely to fall, EBITDA margin to take a hit

Narnolia expects EBITDA margin to decline by 171 bps YoY to 15.9 percent in Q4FY19 on account of increased remediation cost related to inspection in Somerset and Mandideep facilities.

Options trade | A broken wing Iron Condor trade in Lupin

A broken wing Iron Condor trade in Lupin ahead of its results

Lupin gets 4 observations from USFDA after closure of pharmacovigilance inspection

The USFDA issues an EIR to an establishment that is the subject of an FDA or FDA-contracted inspection following the closure of the inspection.

Lupin gets more time from govt to complete project in Indore SEZ

The company is setting up its pharma unit in Indore SEZ to manufacture pharmaceutical formulations metered dose inhalers and dry powder inhalers.

Lupin gets tentative nod from USFDA to market its Fosaprepitant injection

The company has received tentative approval from the USFDA to market its Fosaprepitant for injection in the strength of 150 mg single-dose vial.

Lupin, Zydus Pharmaceuticals recall products in the US

Lupin Somerset is recalling the drug in various strengths due to "failed impurities/degradation specifications", the latest enforcement report by the USFDA said.

Lupin-Natco get USFDA nod to market generic hypertension drug

The approval by the United States Food and Drug Administration (USFDA) is for marketing Bosentan tablets in the strengths of 62.5 mg and 125 mg, Lupin said in a statement.

Lupin falls 3% after Jefferies remains underweight, sees 21% downside

Jefferies said OAI status for Indore unit-II can delay clearance by 6-9 months and it is the 3rd facility to receive OAI in past 2 months

Lupin's Pithampur facility may face regulatory action, says USFDA

The Mumbai-based drugmaker, however, said it does not believe that the classification would have an impact on disruption of supplies or the existing revenues from operations of this facility.

Lupin gains 4% after Morgan Stanley increases target price by 40%

In the past two and four years, Lupin has fallen 42 percent and 53 percent respectively, versus 33 percent and 38 percent gains in the BSE Sensex.

Lupin seeks more time from commerce ministry to complete project in Indore SEZ

The company is setting up its pharma unit in Indore SEZ to manufacture pharmaceutical formulations - metered dose inhalers and dry powder inhalers.

Lupin gets USFDA nod to market generic depression drug

The company has received approval from the US Food and Drug Administration to market its product which is a generic version of Eli Lilly and Company's Prozac tablets.

Lupin Q4 PAT may dip 62.8% YoY to Rs. 253.2 cr: Prabhudas Lilladher

Net Sales are expected to increase by 2.1 percent Y-o-Y (down 7.2 percent Q-o-Q) to Rs. 4,061 crore, according to Prabhudas Lilladher.

Lupin launches testosterone gel in US

Lupin's testosterone gel, 1.62 percent (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie Inc's AndroGel, 1.62 percent, Lupin said in a BSE filing.

Lupin gains 2% as co launches Testosterone gel in US

The drug is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Lupin gets USFDA nod to market testosterone gel

The company has received approval from the United States Food and Drug Administration (USFDA) to market its generic testosterone gel, 1.62 per cent (20.25 mg/1.25 g pump actuation), Lupin said in a statement.